Thermo Fisher Scientific Inc.

NYSE:TMO  
507.81
-8.80 (-1.70%)
4:20:16 PM EDT: $507.19 -0.62 (-0.12%)
Products

FDA Approves Selpercatinib For Locally Advanced Or Metastatic Ret Fusion-Positive Non-Small Cell Lung Cancer

Published: 09/21/2022 22:20 GMT
Thermo Fisher Scientific Inc. (TMO) - FDA Approves Selpercatinib for Locally Advanced Or Metastatic Ret Fusion-positive Non-small Cell Lung Cancer.
FDA Says Also Approved the Oncomine Dx Target (odxt) Test (thermo Fisher Scientific) As a Companion Diagnostic for Selpercatinib.
Further Company Coverage: Tmon ((reuters.
Briefs@thomsonreuters.
Com;)).